placebo + iv sildenafil
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension, Familial Persistent, of the Newborn
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Trial Timeline
Aug 5, 2013 → Sep 28, 2020
NCT ID
NCT01720524About placebo + iv sildenafil
placebo + iv sildenafil is a phase 3 stage product being developed by Pfizer for Pulmonary Hypertension, Familial Persistent, of the Newborn. The current trial status is completed. This product is registered under clinical trial identifier NCT01720524. Target conditions include Pulmonary Hypertension, Familial Persistent, of the Newborn.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Hypertension, Familial Persistent, of the Newborn were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01720524 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Hypertension, Familial Persistent, of the Newborn